{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:47:59Z","timestamp":1760622479353},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.pupt.2005.04.003","type":"journal-article","created":{"date-parts":[[2005,6,21]],"date-time":"2005-06-21T17:38:07Z","timestamp":1119375487000},"page":"112-119","source":"Crossref","is-referenced-by-count":10,"title":["Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Graeme P.","family":"Currie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Rossiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean A.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel K.C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen J.","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2005.04.003_bib1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 1","key":"10.1016\/j.pupt.2005.04.003_bib2","first-page":"1","article-title":"Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care","volume":"59","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2005.04.003_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2005.04.003_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1164\/rccm.200408-1054OC","article-title":"Exacerbations and time spent outdoors in chronic obstructive pulmonary disease","volume":"171","author":"Donaldson","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib6","doi-asserted-by":"crossref","unstructured":"Sestini P, Renzoni E, Robinson S, Poole P, Ram PSF. Short acting beta-2 agonists for stable chronic obstructive pulmonary disease. The Cochrane Library. Oxford: Update Software 2003; Issue 3. Ref ID: 819","DOI":"10.1002\/14651858.CD001495"},{"key":"10.1016\/j.pupt.2005.04.003_bib7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm.163.5.9903053","article-title":"Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease","volume":"163","author":"Rennard","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib9","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib10","doi-asserted-by":"crossref","unstructured":"In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994;105:1411-1419.","DOI":"10.1378\/chest.105.5.1411"},{"key":"10.1016\/j.pupt.2005.04.003_bib11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/ajrccm.160.2.9901038","article-title":"Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease","volume":"160","author":"O'Donnell","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1164\/ajrccm.158.5.9804004","article-title":"Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease","volume":"158","author":"O'Donnell","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib13","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1378\/chest.117.2_suppl.42S","article-title":"Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful?","volume":"117","author":"O'Donnell","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF03257163","article-title":"Long-Acting beta(2)-Agonists: Comparative Pharmacology and Clinical Outcomes","volume":"1","author":"Van Der Woude","year":"2002","journal-title":"Am J Respir Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1476-5381.1994.tb17047.x","article-title":"The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus In vitro","volume":"113","author":"Kallstrom","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2005.04.003_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1183\/09031936.98.11030583","article-title":"Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi","volume":"11","author":"Molimard","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/thx.48.5.547","article-title":"Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism","volume":"48","author":"Linden","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2005.04.003_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1164\/ajrccm.160.1.9901063","article-title":"Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients","volume":"160","author":"Palmqvist","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1034\/j.1399-3003.1999.13e10.x","article-title":"Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction","volume":"13","author":"Politiek","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(00)03611-4","article-title":"Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial","volume":"357","author":"Tattersfield","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2005.04.003_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1164\/rccm.200407-884OC","article-title":"Budesonide\/Formoterol combination therapy as both maintenance and reliever medication in asthma","volume":"171","author":"O'Byrne","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib22","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib23","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial","volume":"353","author":"Vestbo","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2005.04.003_bib24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1183\/09031936.02.00301702","article-title":"Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study","volume":"20","author":"Wadbo","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1183\/09031936.02.00240902","article-title":"Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial","volume":"19","author":"Aalbers","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","article-title":"An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)","volume":"10","author":"Boyd","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1034\/j.1399-3003.2000.15e11.x","article-title":"Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium","volume":"15","author":"van Noord","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib31","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1378\/chest.118.6.1576","article-title":"Additive effects of salmeterol and fluticasone or theophylline in COPD","volume":"118","author":"Cazzola","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib34","first-page":"CD001104","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation","author":"Appleton","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pupt.2005.04.003_bib35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"Bmj"},{"key":"10.1016\/j.pupt.2005.04.003_bib36","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1164\/ajrccm.163.1.2005009","article-title":"Health status deterioration in patients with chronic obstructive pulmonary disease","volume":"163","author":"Spencer","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2005.04.003_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1081-1206(10)61497-4","article-title":"Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function","volume":"93","author":"Lee","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pupt.2005.04.003_bib40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(00)02581-2","article-title":"Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study","volume":"356","author":"Brutsche","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2005.04.003_bib41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02718145","article-title":"The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease","volume":"168","author":"Chapman","year":"1990","journal-title":"Lung"},{"key":"10.1016\/j.pupt.2005.04.003_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198408163110701","article-title":"Role of the parasympathetic system in airway obstruction due to emphysema","volume":"311","author":"Gross","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib43","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1164\/arrd.1984.129.5.856","article-title":"Anticholinergic, antimuscarinic bronchodilators","volume":"129","author":"Gross","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.pupt.2005.04.003_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0024-3205(93)90312-Q","article-title":"Ba 679 BR, a novel long-acting anticholinergic bronchodilator","volume":"52","author":"Disse","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.pupt.2005.04.003_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/089426801316970268","article-title":"Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity","volume":"14","author":"Chodosh","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib46","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1378\/chest.117.2_suppl.63S","article-title":"The pharmacological properties of tiotropium","volume":"117","author":"Barnes","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib47","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.118.5.1294","article-title":"The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group","volume":"118","author":"Casaburi","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib48","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0954-6111(03)00131-8","article-title":"Tolerance to bronchodilating effects of salmeterol in COPD","volume":"97","author":"Donohue","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1183\/09031936.02.00238002","article-title":"Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease","volume":"19","author":"van Noord","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pupt.2004.10.003","article-title":"One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium","volume":"18","author":"Anzueto","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2005.04.003_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/COPD-200026934","article-title":"Clincial trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial","volume":"1","author":"Decramer","year":"2004","journal-title":"J COPD"},{"key":"10.1016\/j.pupt.2005.04.003_bib52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2005.04.003_bib53","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1183\/09031936.04.00085804","article-title":"Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD","volume":"23","author":"McNicholas","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1164\/ajrccm.162.1.9909054","article-title":"Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease","volume":"162","author":"Taube","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib55","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1378\/chest.124.5.1743","article-title":"Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes","volume":"124","author":"Celli","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib57","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1476-5381.1994.tb17128.x","article-title":"Beta-adrenoceptors mediate inhibition of [3H]-acetylcholine release from the isolated rat and guinea-pig trachea: role of the airway mucosa and prostaglandins","volume":"113","author":"Wessler","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pupt.2005.04.003_bib58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/pupt.1998.0121","article-title":"Do parasympatholytic effects of long-acting beta 2-sympathomimetics contribute to their relaxant effects in airway smooth muscle cells?","volume":"11","author":"Teschemacher","year":"1998","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2005.04.003_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pupt.2003.09.001","article-title":"The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD","volume":"17","author":"Cazzola","year":"2004","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2005.04.003_bib60","first-page":"354","article-title":"Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease","volume":"65","author":"Gross","year":"1998","journal-title":"Dey Combination Solution Study Group. Respiration"},{"key":"10.1016\/j.pupt.2005.04.003_bib61","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1164\/ajrccm.161.4.9903044","article-title":"Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease","volume":"161","author":"Littner","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2005.04.003_bib62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib63","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/thorax.58.10.855","article-title":"Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease","volume":"58","author":"Calverley","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2005.04.003_bib64","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1378\/chest.125.5.1726","article-title":"The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD","volume":"125","author":"Hasani","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2005.04.003_bib65","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1183\/09031936.04.00116004","article-title":"Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD","volume":"23","author":"O'Donnell","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2005.04.003_bib66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/thorax.55.4.289","article-title":"A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group","volume":"55","author":"van Noord","year":"2000","journal-title":"Thorax"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553905000556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553905000556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:23:57Z","timestamp":1683120237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553905000556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1094553905000556"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2005.04.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}